|
|
|
|
| LEADER |
02148nam a2200241 u 4500 |
| 001 |
EB002191853 |
| 003 |
EBX01000000000000001329318 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Glyopyrrolate oral solution (Cuvposa -- Medexus Pharmaceuticals, Inc.)
|h Elektronische Ressource
|b indication: chronic severe drooling, neurologic (pediatric)
|
| 246 |
3 |
1 |
|a Glyopyrrolate oral solution (Cuvposa -- Medexus Pharmaceuticals, Inc.)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c [2020], 2020
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK565508
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Glycopyrrolate has a Health Canada indication to reduce chronic, severe drooling in patients three to 18 years old with neurologic conditions associated with problem drooling (e.g., cerebral palsy). Glycopyrrolate is a synthetic quaternary ammonium anticholinergic drug that does not easily cross the blood-brain barrier. Glycopyrrolate inhibits the action of acetylcholine on salivary glands, thereby reducing the extent of salivation. It is available as an oral solution (1 mg/5 mL), with each mL containing 0.2 mg of glycopyrrolate. The Health Canada-recommended dosage is to initiate glycopyrrolate oral solution at 0.02 mg per kg of body weight three times DRUG REIMBURSEMENT RECOMMENDATION Glycopyrrolate Oral Solution (Cuvposa) - CDEC Meeting - November 20, 2019;CDEC Reconsideration Meeting - June 17, 2020; Notice of Final Recommendation - June 24, 20204daily and titrate in increments of 0.02 mg/kg every five to seven days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily, not to exceed 1.5 mg to 3 mg per dose based on weight
|